Metabolic reprogramming in adenomyosis: current evidence, biological mechanisms and therapeutic perspectives

In: Frontiers in Endocrinology · 2026 · vol. 17 , pp. 2019610 · doi:10.3389/fendo.2026.2019610 · W7237047072
Review OA: gold CC0

Abstract

Background Adenomyosis (AM) is a common reproductive disorder in which endometrial glands and stroma are present within the myometrium. Although endocrine, inflammatory, fibrotic and tissue-injury mechanisms are well described, the metabolic adaptations associated with lesion persistence, tissue repair and the uterine microenvironment are only beginning to be defined. At present, no metabolic biomarker has been validated for routine selection of AM treatment. Main body Recent human metabolomic, lipidomic, transcriptomic and functional studies indicate alterations in glycolysis, mitochondrial metabolism, lipid metabolism, redox regulation and ferroptosis-related pathways. Importantly, these changes are context dependent. Reduced glycolytic activity has been associated with impaired eutopic endometrial repair and heavy menstrual bleeding, whereas enhanced glycolysis has been reported in lesion-containing myometrium; increased cytochrome-c oxidase and ATP synthase content has also been reported in endometrial tissue from women with AM. Myometrial lipidomics and immune–metabolic analyses further support heterogeneous metabolic states. We evaluate how these alterations may interact with hypoxia, inflammation, fibrosis, angiogenesis and endocrine signalling while distinguishing direct AM evidence from inference derived from other disease models. We also examine whether traditional Chinese medicine (TCM) blood-stasis-related phenotypes can serve as clinically defined strata for prospective metabolic studies. Current evidence does not justify assigning any TCM syndrome to a specific metabolic pathway or treating these phenotypes as validated molecular subtypes. Finally, we discuss established hormonal treatment alongside emerging metabolism-related strategies, including metformin, glycolysis modulation, ferroptosis-related approaches, sphingosine-1-phosphate (S1P) signalling and TCM-derived interventions. Conclusions Metabolic reprogramming is an emerging component of AM biology, but the available evidence supports tissue- and phenotype-specific alterations rather than a single global metabolic state. A disease-wide statement such as “AM exhibits enhanced glycolysis” is insufficiently precise. Prospectively, compartment-resolved and flux-based studies are required before metabolic signatures can be translated into validated biomarkers or treatment-selection tools.

My notes (saved in your browser only)

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (88)

Source provenance

openalex
last seen: 2026-11-22T06:06:27.128750+00:00
License: CC0 · commercial use OK